Dopamine agonists in prevention of ovarian hyperstimulation syndrome

Kasum, Miro; Vrčić, Hrvoje; Stanić, Patrik; Ježek, Davor; Orešković, Slavko; Beketić-Orešković, Lidija; Pekez, Marijeta

doi:10.3109/09513590.2014.943716

Cited by 15 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the use of cabergoline is recommended and it is suggested that treatment be commenced on the day of hCG trigger at a dose of 0.5 mg for 8 days [ 86 ].…”

Section: Resultsmentioning

confidence: 99%

Prevention of Ovarian Hyperstimulation Syndrome: A Review

Smith

Osianlis

Vollenhoven

2015

Obstetrics and Gynecology International

View full text Add to dashboard Cite

The following review aims to examine the available evidence to guide best practice in preventing ovarian hyperstimulation syndrome (OHSS). As it stands, there is no single method to completely prevent OHSS. There seems to be a benefit, however, in categorizing women based on their risk of OHSS and individualizing treatments to curtail their chances of developing the syndrome. At present, both Anti-Müllerian Hormone and the antral follicle count seem to be promising in this regard. Both available and upcoming therapies are also reviewed to give a broad perspective to clinicians with regard to management options. At present, we recommend the use of a “step-up” regimen for ovulation induction, adjunct metformin utilization, utilizing a GnRH agonist as an ovulation trigger, and cabergoline usage. A summary of recommendations is also made available for ease of clinical application. In addition, areas for potential research are also identified where relevant.

show abstract

“…Therefore, the use of cabergoline is recommended and it is suggested that treatment be commenced on the day of hCG trigger at a dose of 0.5 mg for 8 days [ 86 ].…”

Section: Resultsmentioning

confidence: 99%

Prevention of Ovarian Hyperstimulation Syndrome: A Review

Smith

Osianlis

Vollenhoven

2015

Obstetrics and Gynecology International

View full text Add to dashboard Cite

show abstract

“…Cabergoline is an ergot derivative with high affinity for D 2 dopamine receptors, which cause inhibition of PRL secretion (Romagnoli et Short communication: The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior al., 2009). In nonruminant animals, cabergoline has a much longer half-life (~70 h) than quinagolide (17 h), and it also has less adverse effects than quinagolide (Kasum et al, 2014). However, in cattle, half-life of cabergoline has been reported to be ~20 h (Velactis; European Medicines Agency, 2014).…”

Section: Short Communicationmentioning

confidence: 96%

“…It is interesting to note that 15 d after dry-off, serum PRL concentrations were still lower (P < 0.05) in CAB than in CTRL cows. The half-life of cabergoline has been reported to be about 70 h (Kasum et al, 2014) in dogs and mice and about 20 h in cattle (Velactis SPC Mexico; C646.2.03.E.0). The results herein showed a sustained decrease in serum PRL concentrations 15 d after injection, in line with studies in other species showing a persistent effect of cabergoline on serum PRL concentration (Ferrari et al, 1986;Mattei et al, 1988).…”

Section: Short Communicationmentioning

confidence: 98%

Short communication: The effects of cabergoline administration at dry-off of lactating cows on udder engorgement, milk leakages, and lying behavior

Bach

De-Prado

Arı́s

2015

Journal of Dairy Science

View full text Add to dashboard Cite

Cabergoline is an ergot derivative with high affinity for the D2 dopamine receptors whose dopaminergic effects cause inhibition of prolactin (PRL) secretion; thus, it could be considered a molecule that acts as a potential dry-off facilitator. One hundred ninety-nine Holstein cows (102 primiparous; 97 multiparous) producing ≥ 18 kg/d at dry-off were split in 2 treatments to evaluate the effects of diminishing PRL secretion at dry-off (between 70 and 50 d from the expecting calving date) on udder engorgement, milk leakage, and cow well-being after dry-off. Treatments consisted of a single i.m. injection of 5 mL of a solution containing 5.6 mg of cabergoline (CAB; Velactis, Ceva Santé Animal, Libourne, France) or 5 mL of saline solution as a placebo (CTRL). Each animal was evaluated for presence or absence of milk leakages during the 4 d following dry-off and udder engorgement was determined using a digital algometer. Lying behavior was recorded during 10 d after dry-off. Twenty-five cows from each treatment were randomly chosen and blood sampled at 3 and 15 d after dry-off, and again at 5 and 3 d before the expected calving date to determine serum PRL concentrations. Cows on CAB had lower serum PRL concentrations than cows on CTRL at 3 and 15 d after dry-off. Average udder engorgement was lower for cows on CAB than for cows on CTRL following dry-off, and it decreased as days after dry-off increased. The overall incidence of milk leakage in cows on CAB (3.1 ± 0.88%) was 73.5% of that obtained in cows on CTRL (11.7 ± 1.64%); cows on CAB had 0.2 lower odds of incurring milk leakage than cows on CTRL. The day following dry-off, CAB cows lied about 1.5h/d more than cows on CTRL. We conclude that i.m. administration of 5.6 mg of cabergoline at dry-off effectively reduces PRL secretion, udder engorgement, and milk leakages, and improves lying time the day following dry-off.

show abstract

“…In addition, different administration regimens of Bromo are used to treat Parkinson's disease (Perez-Lloret and Rascol, 2010), as well as the ovarian hyperstimulation syndrome (Gomez et al, 2006;Kasum et al, 2014), although favorable outcomes related to these diseases have been achieved. The results of the present study suggest that alteration of the permeability of the BBB may be an adverse effect after prolonged treatment with the drug and in cases where Bromo completely inhibits PRL production.…”

Section: Discussionmentioning

confidence: 99%